Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/19260Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Miltiadous, G. | en |
| dc.contributor.author | Saougos, V. | en |
| dc.contributor.author | Cariolou, M. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.date.accessioned | 2015-11-24T18:58:15Z | - |
| dc.date.available | 2015-11-24T18:58:15Z | - |
| dc.identifier.issn | 0091-7370 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/19260 | - |
| dc.rights | Default Licence | - |
| dc.subject | Anticholesteremic Agents/*therapeutic use | en |
| dc.subject | Cholesterol, LDL/*blood | en |
| dc.subject | Humans | en |
| dc.subject | Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use | en |
| dc.subject | Hyperlipoproteinemia Type II/blood/*drug therapy | en |
| dc.subject | Lipoprotein(a)/*blood | en |
| dc.subject | Statistics, Nonparametric | en |
| dc.title | Plasma lipoprotein(a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolemia | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/16951279 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2006 | - |
| heal.abstract | Familial hypercholesterolemia (FH) is characterised by elevated plasma LDL-cholesterol levels and premature ischemic heart disease. Statin therapy is mandatory in order to prevent atherosclerosis in patients with heterozygous FH. Both genetic and environmental factors affect the statin-induced LDL-cholesterol lowering effect in patients with heterozygous FH. Recently published data suggest that plasma lipoprotein(a) levels may affect the efficacy of statin therapy in patients with nephrotic syndrome. However, no data are available concerning the effect of lipoprotein(a) levels on the efficacy of statin therapy in patients with heterozygous FH. This report demonstrates negative correlation between plasma lipoprotein(a) levels and the LDL-cholesterol lowering effect of statin therapy in 49 patients with heterozygous FH. | en |
| heal.journalName | Ann Clin Lab Sci | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Elisaf-2006-plasma lipoprotein(a) levels.pdf | 145.77 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
